POLB 001 European Patent granted

AI SummaryClose X

Poolbeg Pharma PLC has been granted a European patent for POLB 001, a p38 MAP kinase inhibitor, strengthening its intellectual property portfolio for the treatment of severe influenza and cancer immunotherapy-induced Cytokine Release Syndrome (CRS), a market estimated at over US$10 billion. This patent enhances the value and appeal of POLB 001 to potential partners by covering its use in these significant therapeutic areas.

Disclaimer*

UK 100

Latest directors dealings